Prostate cancer (PCa) is the second most common cancer in men worldwide and has the highest incidence rate in developed countries ([@djz124-B1]). Among common cancers at 11 anatomical sites, PCa was found to be the most heritable ([@djz124-B2]), and genome-wide association studies have identified more than 150 variants associated with PCa ([@djz124-B3]). However, the identified variants were common and had low penetrance, limiting the clinical utility of genetic risk scores ([@djz124-B4],[@djz124-B5]). Familial clustering of PCa has been reported ([@djz124-B6]), and around 5% of PCa cases could be primarily attributable to rare, highly penetrant mutations in genes such as *BRCA1*, *BRCA2*, and *HOXB13* ([@djz124-B7]).

Genetic testing using multigene panels has the potential to guide PCa screening, targeted treatment, and surveillance for patients and their relatives ([@djz124-B8]). Because variants in genes such as *BRCA1* and *BRCA2* are associated with increased risk of multiple cancer types including PCa ([@djz124-B9]), identifying pathogenic variants in patients with PCa has implications for surveillance of various cancer types in relatives. Patients with a pathogenic variant in *ATM*, *BRCA2*, and *CHEK2* are reported to have a higher risk for metastatic PCa ([@djz124-B10]). Patients with metastatic PCa who have germline or somatic mutations in DNA-repair machinery have sustained responses to poly--adenosine diphosphate ribose polymerase inhibitors ([@djz124-B11]) and platinum-based chemotherapy ([@djz124-B12]). The ongoing IMPACT study (NCT00261456) is evaluating the use of targeted PCa screening in men with *BRCA1*/2 mutations ([@djz124-B13]). However, no centralized guidelines for PCa genetic testing exist.

Guidelines for genetic testing serve as a resource to identify individuals who may benefit from cancer-risk assessment and genetic counseling, to guide decisions related to genetic testing, and to facilitate a multidisciplinary approach in managing individuals at increased risk ([@djz124-B9]). In contrast to breast, ovarian ([@djz124-B9]), and colon cancers ([@djz124-B14]), studies on PCa have been limited, and information regarding the clinical significance of genetic variants in ClinVar is much sparser than information available for other cancers. In this setting, a large-scale, case-control study could provide important information on classifications of individual germline variants, PCa disease risk for each gene, and demographic and clinical characteristics of patients bearing pathogenic variants. Although most studies have analyzed only patients with PCa ([@djz124-B8]), our previous study on breast cancer ([@djz124-B15]) showed that population-matched control individuals were indispensable because 5% or fewer variants found in Japanese patients were registered in the most closely matched population in ExAC ([@djz124-B16]). Therefore, various types of information from a large-scale, case-control study would help in developing guidelines for genetic testing in PCa.

In this study, we performed the largest case-control sequencing study on PCa heredity (to the best of our knowledge), involving 7636 unselected Japanese patients with PCa and 12 366 control participants. We sequenced coding regions of eight genes ([@djz124-B7]), assigned clinical significance for all variants detected, and calculated PCa risk estimates for presumed pathogenic variants in each gene. We investigated the demographic and clinical characteristics of patients with pathogenic variants.

Methods
=======

Study Population
----------------

We obtained all study samples from BioBank Japan ([@djz124-B17],[@djz124-B18]), which is a multi-institutional, hospital-based registry that collects DNA and clinical information from patients with various common diseases, including PCa ([@djz124-B19]), from all over Japan between 2003 and 2018. Clinical characteristics of cases and control individuals were collected by interview or medical record survey using a standard questionnaire at the point of entry to Biobank Japan. These PCa samples are considered likely to be representative of Japanese patients because the age-specific distribution of PCa patients in BioBank Japan was similar to that described in the Japanese Ministry of Health, Labour, and Welfare Patient Survey ([@djz124-B19]). In this study, we performed a hospital registry-based study in 7744 patients with PCa and 12 520 male controls. Among the 7744 patients with PCa, 7229 individuals were diagnosed before enrollment, and the remaining 515 patients were diagnosed during a follow-up period. We used the same 12 520 male controls age 60 years and older with no personal or family history of cancer from our previous study on breast cancer ([@djz124-B15]). Owing to this selection criterion, the control group may exhibit a lower frequency of pathogenic variants than that observed in the general controls individuals, and as a result, disease risk may be calculated to be higher. All participants provided their written informed consent. The study was approved by the ethical committees of the Institute of Medical Sciences, the University of Tokyo, and the RIKEN Center for Integrative Medical Sciences.

Sequencing and Bioinformatics Analysis
--------------------------------------

We selected eight genes (*ATM*, *BRCA1*, *BRCA2*, BRCA1 interacting protein C-terminal helicase 1 \[*BRIP1*\], *CHEK2*, *HOXB13*, *NBN*, and *PALB2*) whose rare germline variants were reported to show high penetrance for PCa in a review article ([@djz124-B7]) because there were no guidelines about gene selection for genetic testing. We analyzed the complete coding regions and 2-bp flanking intronic sequences of all eight genes (37 982 bp) by a multiplex polymerase chain reaction--based target sequence method ([@djz124-B20]) ([Supplementary Methods](#sup1){ref-type="supplementary-material"}, available online). Finally, we identified 1456 genetic variants in 7636 patients and 12 366 control individuals, and 99.98% of the target region was covered by at least 20 sequence reads.

Annotation of Variants
----------------------

We assigned clinical significance (pathogenic, benign, or uncertain) for all variants as in our previous study ([@djz124-B15]) ([Supplementary Methods](#sup1){ref-type="supplementary-material"}, available online). Briefly, we determined clinical significance using the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines ([@djz124-B21],[@djz124-B22]) ([Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"}, available online) as well as pathogenicity assertions registered in ClinVar ([@djz124-B23]). We used the same procedure for all genes except *HOXB13* because a gain-of-function missense variant in *HOXB13* was considered pathogenic ([@djz124-B24]). We considered variants as pathogenic based on classification as pathogenic by the ACMG/AMP guidelines and/or classification as pathogenic in ClinVar. Specific details are described in [Supplementary Methods](#sup1){ref-type="supplementary-material"} (available online). Variants not registered in ClinVar on August 1, 2017, were considered novel.

Statistical Analysis
--------------------

Case-control association analysis was performed using Fisher exact test under a dominant model. To investigate the association of pathogenic variants with demographic and clinical characteristics, we used *t* tests for continuous variables and Fisher exact tests or Cochran-Armitage tests for discrete variables. All statistical tests were two-sided, and *P* less than .05 was considered statistically significant except when Bonferroni correction was applied for the association analysis between each of the eight genes and PCa (*P* \< .006 = 0.05/8). All analyses were performed using R statistical package (ver. 3.1.3).

Results
=======

Demographic and Clinical Characteristics of Participants
--------------------------------------------------------

The mean age at PCa diagnosis was 71.0 years (SD = 6.9) ([Table 1](#djz124-T1){ref-type="table"}). Positive smoking history in cases (69.4%) was statistically significantly lower than that in controls (76.1%, *P* \< .001). This reflects the fact that this proportion was the fifth smallest among 42 male diseases registered in the BioBank Japan ([@djz124-B17]), whereas control participants consisted of patients with complex diseases other than cancer in the same biobank. Family history of prostate, breast, or pancreatic cancers was observed in 6.8%, 4.7%, and 3.3% of patients, respectively. Other clinical characteristics are shown in [Table 1](#djz124-T1){ref-type="table"}.

###### 

Demographic and clinical characteristics of study participants

  Variable                                                            PCa patients      Controls
  ------------------------------------------------------------------ -------------- ----------------
  No. of participants                                                  7744 (100)     12 520 (100)
  Mean age at entry, (SD), y                                           72.9 (7.1)      70.4 (7.0)
  Mean age at diagnosis, (SD), y[\*](#tblfn1){ref-type="table-fn"}     71.0 (6.9)         ---
  Smoking history                                                                   
   Yes                                                                5263 (69.4)     9490 (76.1)
   No                                                                 2322 (30.6)     2984 (23.9)
   Missing                                                                159              46
  Alcohol drinking history                                                          
   Yes                                                                5307 (70.0)     8698 (69.9)
   No                                                                 2270 (30.0)     3751 (30.1)
   Missing                                                                167              71
  Body mass index, (SD) kg/m^2^[\*](#tblfn1){ref-type="table-fn"}      23.4 (2.9)      23.4 (3.1)
  Family history of PCa                                                             
   Yes                                                                 530 (6.8)         0† (0)
   No                                                                 7214 (93.2)    12 520 (100.0)
  Family history of breast cancer                                                   
   Yes                                                                 362 (4.7)         0† (0)
   No                                                                 7382 (95.3)    12 520 (100.0)
  Family history of pancreatic cancer                                               
   Yes                                                                 255 (3.3)         0† (0)
   No                                                                 7489 (96.7)    12 520 (100.0)
  Histological type                                                                 
   Adenocarcinoma                                                     7085 (99.5)         ---
   Others                                                               38 (0.5)          ---
   Missing                                                                621             ---
  TNM classification: T                                                             
   T4                                                                  172 (4.5)          ---
   T3                                                                  805 (20.9)         ---
   T2                                                                 1794 (46.5)         ---
   T1                                                                 1080 (28.0)         ---
   T0                                                                   9 (0.2)           ---
   Missing                                                                3884            ---
  TNM classification: N                                                             
   N1                                                                  229 (6.1)          ---
   N0                                                                 3517 (93.9)         ---
   Missing                                                                3998            ---
  TNM classification: M                                                             
   M1                                                                  297 (8.0)          ---
   M0                                                                 3397 (92.0)         ---
   Missing                                                                4050            ---
  Gleason score                                                                     
   Aggressive (≥8)                                                    1713 (29.7)         ---
   Indolent (\<8)                                                     4064 (70.3)         ---
   Missing                                                                1967            ---
  Maximum value of serum PSA before treatment, ng/mL                                
   \>20                                                               1470 (31.0)         ---
   10--20                                                             1117 (23.5)         ---
   4--10                                                              1991 (42.0)         ---
   ≤4                                                                  166 (3.5)          ---
   Missing                                                                3000            ---
  Complicated with benign prostatic hypertrophy                                     
   Yes                                                                2722 (57.8)         ---
   No                                                                 1985 (42.2)         ---
   Missing                                                                3037            ---

The number of missing data is 311 in mean age at diagnosis; 268 in cases and 753 in controls in body mass index. PCa = prostate cancer; PSA = prostate- specific antigen. Em dashes (---) indicate no information for control participants.

Controls with no past history or family history of cancers were selected for this study. TNM = Tumor, Node, Metastasis.

Pathogenic Germline Variants
----------------------------

Sequencing of the eight PCa-relevant genes identified 1456 germline variants in total. We categorized the variants according to the ACMG/AMP guidelines as follows: five pathogenic, 117 likely pathogenic, 49 benign, 90 likely benign, two variants of uncertain significance (VUS) with pathogenic as well as benign evidence, and 1193 VUS with insufficient evidence. When we compared these results with assertions in ClinVar ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}, available online), there were no apparent discrepancies (variants that were pathogenic in one classification and benign in the other). Finally, we considered 136, 284 and 1036 variants as pathogenic, benign, and VUS, respectively ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}, available online). Single variant association results are shown in [Supplementary Table 5](#sup1){ref-type="supplementary-material"} (available online) for the 136 pathogenic variants and in [Supplementary Table 6](#sup1){ref-type="supplementary-material"} (available online) for the 284 benign variants and the 1036 VUS. More than one-half (57.4%) of the pathogenic variants were novel, and 71.4% and 61.5% of pathogenic variants in *BRCA1* and *BRCA2*, respectively, were previously described in ClinVar, whereas more than one-half of pathogenic variants in the other genes were novel ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online). We revisited the latest database in ClinVar on February 11, 2019, and other published works to ensure that our data were current. In total, 32 pathogenic variants were reported in four publications or ClinVar. The majority (21 variants) came from our previous large-scale sequencing study on breast cancer ([@djz124-B15]). Finally, 46 of 136 pathogenic variants (33.8%) are still considered novel.

We checked the locations and frequencies of the pathogenic variants ([Figure 1](#djz124-F1){ref-type="fig"}). We observed four frequent pathogenic variants shared in five or more patients: p.Asp1540Asp in *ATM* (n = 12, *P* \< .001, odds ratio \[OR\] = 19.46, 95% confidence interval \[CI\] = 2.88 to 828.78), p.Gly132Glu in *HOXB13* (n = 56, *P* \< .001, OR = 6.08, 95% CI = 3.39 to 11.59), and p.Ile1859fs (n = 11, *P* \< .001, OR = 8.92, 95% CI = 1.95 to 82.99) and p.Arg2318\* (n = 19, *P* \< .001, OR = 15.42, 95% CI = 3.72 to 136.50) in *BRCA2*. The first two variants were novel. Note that we did not observe any association between the carrier status of these four variants and the 10 principal components calculated using single nucleotide polymorphism array data from 6269 of 7636 patients with PCa ([@djz124-B25],[@djz124-B26]). This finding suggests that these pathogenic variants may be spread across Japanese populations.

![Location and number of pathogenic variants in Japanese patients with prostate cancer. Locations of pathogenic variants found in patients (n = 219) and domains in proteins encoded by the six genes are shown by lollipop structures, with the variant type indicated by color. The *x* axis reflects the number of amino acid residues, and the *y* axis shows the total number of patients with each pathogenic variant. HGVS.p of frequent variants with five or more patients are shown, and two variants newly identified as pathogenic variants are **underlined**. ANAPC5 = anaphase-promoting complex subunit 5; BRCT = BRCA1 C terminus; DEAD_2 = DEAD/DEAH box helicase 2; FAT = FRAP, ATM and TRRAP; FATC = FRAP, ATM, TRRAP C-terminal; FHA = forkhead-associated; HOXA13_N= hox protein A13 N terminal; Nbs1_C = DNA damage repair protein Nbs1; NIBRIN_BRCT_II = second BRCT domain on Nijmegen syndrome breakage protein; PALB2_WD40 = partner and localizer of BRCA2 WD40 domain; PI3_PI4_kinase = phosphatidylinositol 3- and 4-kinase; TAN = telomere-length maintenance and DNA damage repair; zf-C3HC4 = zinc finger, C3HC4 type; zf-RING = zinc finger, C3HC4 type.](djz124f1){#djz124-F1}

We compared the frequency of carriers bearing pathogenic variants between cases and controls ([Table 2](#djz124-T2){ref-type="table"}). In total, 2.9% of patients and 0.8% of control participants carried a pathogenic variant (*P* \< .001, OR = 3.66, 95% CI = 2.87 to 4.69). *BRCA2* (*P* \< .001, OR = 5.65, 95% CI = 3.55 to 9.32), *HOXB13* (*P* \< .001, OR = 4.73, 95% CI = 2.84 to 8.19), and *ATM* (*P* \< .001, OR = 2.86, 95% CI = 1.63 to 5.15) were statistically significantly associated with PCa after Bonferroni correction. Only one patient carried two major pathogenic variants (p.Arg2318\* in *BRCA2* and p.Gly132Glu in *HOXB13*). He was diagnosed with T2bN0M0 and GS7 PCa at age 61 years and had no previous cancer history but did have a family history of breast cancer.

###### 

Results of gene-based association test using pathogenic variants

  Gene       No. of pathogenic variants    Case (n = 7636)  Control (n = 12 366)   *P* [\*](#tblfn3){ref-type="table-fn"}   OR† (95% CI)            
  ---------- ---------------------------- ----------------- ---------------------- ---------------------------------------- -------------- -------- ---------------------
  *BRCA2*    52                                  83         1.1                    24                                       0.2            \<.001    5.65 (3.55 to 9.32)
  *HOXB13*   5                                   61         0.8                    21                                       0.2            \<.001    4.73 (2.84 to 8.19)
  *ATM*      31                                  37         0.5                    21                                       0.2            \<.001    2.86 (1.63 to 5.15)
  *BRCA1*    14                                  14         0.2                    10                                       0.1            .06       2.27 (0.94 to 5.71)
  *CHEK2*    9                                   12         0.2                    8                                        0.1            .06       2.43 (0.91 to 6.86)
  *PALB2*    6                                    4         0.1                    4                                        0.0            .49       1.62 (0.30 to 8.70)
  *BRIP1*    12                                   6         0.1                    7                                        0.1            .58       1.39 (0.39 to 4.83)
  *NBN*      7                                    3         0.0                    4                                        0.0            1.00      1.21 (0.18 to 7.18)
  *Sum*      136                                219‡        2.9                    99                                       0.8            \<.001    3.66 (2.87 to 4.69)

Two-sided Fisher exact test was used. BRIP1 = BRCA1 interacting protein C-terminal helicase 1; CI = confidence interval; OR = odds ratio.

Odds ratio for cases bearing pathogenic variants vs controls bearing pathogenic variants.

Because one patient had a pathogenic variant both in *BRCA2* and *HOXB13*, the total number of carriers was one smaller than the sum of carriers in each gene.

Sensitivity Analyses Regarding the Annotation of Variants
---------------------------------------------------------

Various procedures of the ACMG/AMP guidelines ([@djz124-B21]) followed in different laboratories have resulted in different interpretations of variants ([@djz124-B27]). We performed two types of sensitivity analyses. The first sensitivity analysis compared our method to ClinVar. We performed gene-based association analysis using pathogenic variants registered in ClinVar (n = 58, [Supplementary Table 7](#sup1){ref-type="supplementary-material"}, available online) and determined by the ACMG/AMP guidelines (n = 122, [Supplementary Table 8](#sup1){ref-type="supplementary-material"}, available online). The odds ratio of all genes was comparable (ClinVar: OR = 3.99, 95% CI = 2.68 to 6.07; ACMG/AMP: OR = 3.66, 95% CI = 2.84 to 4.74). For each gene, similar odds ratios were observed, with the exception of HOXB13--0/58 pathogenic ClinVar records vs 5/122 ACMG/AMP classifications. These data suggest that our interpretation of the ACMG/AMP guidelines would be comparable with that of ClinVar.

The second sensitivity analysis involves gene-based association analysis of rare benign variants exhibiting Minor allele frequency less than 0.01 (n = 248, [Supplementary Table 9](#sup1){ref-type="supplementary-material"}, available online) and of rare VUS (n = 1036, [Supplementary Table 10](#sup1){ref-type="supplementary-material"}, available online). The gene-based association test using benign variants actually showed no genes possessing a *P* less than .05. Conversely, the gene-based association test using VUS indicated that *CHEK2* exhibited a *P* less than .001 and an OR = 1.62 (95% CI = 1.30 to 2.00). Three missense variants possessed a *P* less than .05, and these included p.Ala496Pro (*P* = .006, OR = 4.22, 95% CI = 1.41 to 15.11), p.Arg223Cys (*P* = .03, OR = 1.98, 95% CI = 1.01 to 3.92), and p.His414Tyr (*P* = .03, OR = 2.25, 95% CI = 1.04 to 4.99). Although p.Arg223Cys possessed sufficient pathogenic (PS3, PM1, and PP3) as well as benign evidence (BS1 and BP5), the others lacked sufficient evidence. Therefore, certain variants within *CHEK2* may be pathogenic, and *CHEK2* may contribute to the development of PCa, although additional research, including functional tests, is required to clarify this issue. It might also suggest further improvement of the ACMG/AMP guidelines.

Demographic and Clinical Characteristics of Patients , With Pathogenic Variants
-------------------------------------------------------------------------------

To investigate the association of pathogenic variants with demographic and clinical characteristics of PCa, we compared these between the 219 carrier patients and the 7417 noncarrier patients ([Table 3](#djz124-T3){ref-type="table"}). The carriers were on average 2.0 years younger at PCa diagnosis (*P* \< .001) and more often had histories of smoking (77.0% in carriers vs 69.2% in noncarriers, *P* = .02) and alcohol drinking (82.6% vs 69.8%, *P* \< .001). Carriers also more often had a family history of breast (11.9% vs 4.5%, *P* \< .001), pancreatic (8.7% vs 3.2%, *P* \< .001), lung (12.3% vs 7.5%, *P* = .01), or liver (7.8% vs 4.6%, *P* = .03) cancers. There was no difference between carriers (8.2%) and noncarriers (6.8%) in family history of PCa (*P* = .41). The carriers also showed worse clinical characteristics in terms of Tumor, Node, Metastasis (TNM) classifications (*P* = .03 and *P* = .04 for T and M, respectively), Gleason score of at least 8 (41.0% vs 29.1%, *P* = .002), and prostate-specific antigen (PSA) greater than 10 (64.0% vs 54.1%, *P* = .02). We also performed logistic regression analysis with carrier status of a pathogenic variant as a dependent variable against these 11 variables because they may be interrelated. We used 2427 of 7636 patients who did not have missing data. [Supplementary Table 11](#sup1){ref-type="supplementary-material"} (available online) indicates that only three variables (age at diagnosis, alcohol drinking history, and family history of breast cancer) showed *P* less than .05, which would be explained by interrelation between some variables and/or the decreased number of samples in this analysis. The other variables should be carefully considered in further studies. We also examined the impact of pathogenic variants on age at PCa diagnosis ([Figure 2, A and B](#djz124-F2){ref-type="fig"}). Pathogenic variants were found in 7.9% of patients diagnosed at younger than 60 years old. The proportion of pathogenic variants statistically significantly decreased with advancing age at diagnosis (*P* \< .001) but was stable between 2% and 3% in individuals age 65 years or older.

![Proportion of patients and genes with pathogenic variants by age groups at prostate cancer diagnosis. **A**) Proportion of patients with pathogenic variants is shown. Two-sided Cochran-Armitage test was used (*P* \< .001). **B**) Proportion of genes with pathogenic variants is shown.](djz124f2){#djz124-F2}

###### 

Statistically significant differences in demographic and clinical characteristics between patients with PCa with and without pathogenic variants

  Variable                                             No. of patients with pathogenic variants (%)   No. of patients without pathogenic variants (%)   *P* [\*](#tblfn6){ref-type="table-fn"}   OR (95% CI)
  ---------------------------------------------------- ---------------------------------------------- ------------------------------------------------- ---------------------------------------- ---------------------
  No. of patients                                      219 (100)                                      7417 (100)                                        ---                                      ---
  Age at diagnosis, mean (SD), y                       69.0 (7.7)                                     71.0 (6.9)                                        \<.001                                   ---
  Smoking history                                                                                                                                                                                
   Yes                                                 167 (77.0)                                     5046 (69.2)                                       .02                                      1.48 (1.07 to 2.09)
   No                                                  50 (23.0)                                      2243 (30.8)                                                                                1.00 (Referent)
  Alcohol drinking history                                                                                                                                                                       
   Yes                                                 180 (82.6)                                     5078 (69.8)                                       \<.001                                   2.05 (1.44 to 3.01)
   No                                                  38 (17.4)                                      2202 (30.2)                                                                                1.00 (Referent)
  Family history of PCa†                                                                                                                                                                         
   Yes                                                 18 (8.2)                                       505 (6.8)                                         .41                                      1.23 (0.71 to 2.01)
   No                                                  201 (91.8)                                     6912 (93.2)                                                                                1.00 (Referent)
  Family history of breast cancer                                                                                                                                                                
   Yes                                                 26 (11.9)                                      333 (4.5)                                         \<.001                                   2.87 (1.80 to 4.40)
   No                                                  193 (88.1)                                     7084 (95.5)                                                                                1.00 (Referent)
  Family history of pancreatic cancer                                                                                                                                                            
   Yes                                                 19 (8.7)                                       234 (3.2)                                         \<.001                                   2.92 (1.69 to 4.78)
   No                                                  200 (91.3)                                     7183 (96.8)                                                                                1.00 (Referent)
  Family history of lung cancer                                                                                                                                                                  
   Yes                                                 27 (12.3)                                      553 (7.5)                                         .01                                      1.73 (1.10 to 2.64)
   No                                                  192 (87.7)                                     6864 (92.5)                                                                                1.00 (Referent)
  Family history of liver cancer                                                                                                                                                                 
   Yes                                                 17 (7.8)                                       340 (4.6)                                         .03                                      1.75 (0.99 to 2.92)
   No                                                  202 (92.2)                                     7077 (95.4)                                                                                1.00 (Referent)
  TNM classification: T                                                                                                                                                                          
   T3/T4                                               37 (33.6)                                      902 (24.6)                                        .03                                      1.56 (1.01 to 2.36)
   T0 -2                                               73 (66.4)                                      2769 (75.4)                                                                                1.00 (Referent)
  TNM classification: M                                                                                                                                                                          
   M1                                                  14 (13.2)                                      270 (7.7)                                         .04                                      1.83 (0.95 to 3.28)
   M0                                                  92 (86.8)                                      3244 (92.3)                                                                                1.00 (Referent)
  Gleason score                                                                                                                                                                                  
   Aggressive (≥8)                                     66 (41.0)                                      1610 (29.1)                                       .002                                     1.70 (1.21 to 2.36)
   Indolent (\<8)                                      95 (59.0)                                      3930 (70.9)                                                                                1.00 (Referent)
  Maximum value of serum PSA before treatment, ng/mL                                                                                                                                             
   \>10                                                87 (64.0)                                      2461 (54.1)                                       .02                                      1.51 (1.04 to 2.19)
   ≤10                                                 49 (36.0)                                      2087 (45.9)                                                                                1.00 (Referent)

Two-sided Fisher exact test was used for all analyses except for age at diagnosis. Two-sided *t* test was used for age at diagnosis. CI = confidence interval; OR = odds ratio; PCa = prostate cancer; PSA = prostate-specific antigen; TNM = Tumor, Node, Metastasis.

Family history of PCa was not associated with carrier status but is shown because its association was expected.

We further analyzed these demographic and clinical characteristics in patients with variants in *ATM* (n = 37), *BRCA2* (n = 83), or *HOXB13* (n = 61) ([Supplementary Table 12](#sup1){ref-type="supplementary-material"}, available online). Although some association tests had limited statistical power because of the low number of carriers, associations with age at diagnosis, smoking history, and alcohol drinking history showed similar tendencies among the three genes. Family history of breast cancer was associated with both variants in *BRCA2* (15.7% in *BRCA2* carriers vs 4.5% in noncarriers, *P* \< .001) and in *HOXB13* (16.4%, *P* \< .001). Family history of pancreatic cancer was associated with variants in *BRCA2* (16.9% in *BRCA2* variant carriers vs 3.2% in noncarriers, *P* \< .001). Patients bearing pathogenic variants of *BRCA2* alone showed worse clinical characteristics as shown by TNM classifications (T: *P* = .001, M: *P* = .008), Gleason score of at least 8 (51.7% in *BRCA2* carriers vs 29.1% in noncarriers, *P* \< .001), and PSA greater than 10 (70.2% vs 54.1%, *P* = .03).

Discussion
==========

We identified 136 pathogenic variants in eight genes in 7636 patients with PCa and 12 366 control individuals. Finally, 33.8% of the pathogenic variants were newly identified in this study. Pathogenic variants were found in 2.9% of unselected Japanese PCa patients; *HOXB13*, *BRCA2,* and *ATM* were the statistically significant causative genes. Patients with pathogenic variants showed specific demographic and clinical characteristics.

The Philadelphia Prostate Cancer Consensus 2017 (the Consensus) was recently published to establish a genetic evaluation framework for inherited PCa ([@djz124-B8]). We investigated if our study results could add more evidence to the Consensus. Regarding gene selection, the Consensus considered that both *BRCA1* and *BRCA2* had high-grade evidence for being related to PCa. However, our results revealed that only *BRCA2* showed a statistically significant contribution to PCa, and patients carrying a pathogenic variant in this gene showed worse clinical characteristics. *BRCA1* pathogenic variants, altogether or considering only the most frequent pathogenic variant observed in patients with breast cancer ([@djz124-B15]), p.Leu63\*, showed no statistically significant association with PCa risk. PCa disease risks were calculated as 5.65 for *BRCA2* and 2.27 for *BRCA1*. This is consistent with results of previous studies ([@djz124-B28]) (*BRCA2*: 4.7--8.6 and *BRCA1*: 1.1--3.8). Therefore, our results suggest that *BRCA1* and *BRCA2* should be separately considered in genetic testing among Japanese patients with PCa.

We validated the importance of *HOXB13*, although its main pathogenic variant in our population, p.Gly132Glu, was different from those in European (p.Gly84Glu) ([@djz124-B24]) and Chinese (p.Gly135Glu) populations ([@djz124-B29]). According to the Genome Aggregation Database ([@djz124-B16]), p.Gly84Glu was also observed in African, Ashkenazi Jewish, and Latino populations, but p.Gly132Glu and p.Gly135Glu were found only in East Asian populations. However, p.Gly132Glu and p.Gly135Glu may be subpopulation specific, given that p.Gly132Glu was not observed in 96 Chinese patients ([@djz124-B29]) and p.Gly135Glu was not found in our Japanese cohort, suggesting that the existence of frequent pathogenic variants in each subpopulation would strongly affect the importance of *HOXB13* in genetic testing for PCa.

We also provided additional support regarding the contribution to PCa of *ATM* with emerging evidence in the Consensus ([@djz124-B8]). *NBN* also had the same level of evidence, but we did not observe any contribution from this gene in this study of Japanese individuals. The primary evidence supporting a role of *NBN* came from 657del5 (p.Lys219Asnfs, rs587776650) in a Polish population ([@djz124-B30]), but this variant was not observed in our Japanese population. Therefore, the lack of association in this study indicates less importance of this gene in Japanese PCa rather than evidence against association in other populations. We did not observe the importance of *CHEK2* and *PALB2* with low or insufficient evidence in the Consensus ([@djz124-B8]). Taken together, the Japanese data provide evidence about the contribution of each gene to PCa and also highlight the importance of population-specific data for genetic testing.

Regarding the selection of patients for genetic testing in the Consensus, we validated the importance of family histories of breast and pancreatic cancers. Our results also showed weaker associations with family history of lung and liver cancers. Note that we did not detect a statistically significant association with family history of PCa, although it is recognized as an established risk factor ([@djz124-B7]). Because the proportion of patients with a family history of PCa was lower (6.8%) in Japan than that reported elsewhere at 10--15% ([@djz124-B31]), this finding might be explained by a lower incidence of PCa in the Japanese population ([@djz124-B32]). However, because incidence of PCa ([@djz124-B32]) and life expectancy ([@djz124-B33]) are rapidly increasing in Japan, family histories of PCa would presumably become useful for the next generation to be aware of. The importance of age at diagnosis was confirmed because patients who were younger at diagnosis were more likely to carry pathogenic variants. We also observed associations between smoking and alcohol drinking histories with carrier status, although its importance was not previously recognized ([@djz124-B34]). Taken together, our results provide a series of additional and unexpected evidence above and beyond the Consensus ([@djz124-B8]), which should inform genetic testing in PCa and promote studies about specific questions in other populations internationally.

This study had some limitations. First, risks associated with pathogenic variants might be overestimated because we selected controls age 60 years and older with no individual or family history of cancers, although the disease risk for *BRCA1/2* variants was comparable with that found in previous studies. Second, we focused on eight genes based on a review article ([@djz124-B7]) because the Consensus did not exist when this study started. The Consensus ([@djz124-B8]) proposed DNA mismatch repair genes for Lynch syndrome, although they have less support than *BRCA1*/2 and *HOXB13*. Third, we derived the variant classifications against ACMG/AMP criteria ([@djz124-B21]) using an automated approach and recognize that additional manual curation is required to ensure "clinical-grade" classifications. Finally, we considered gain-of-function missense variants in *HOXB13* as pathogenic based on the previous publications examining European ([@djz124-B24]) and Chinese ([@djz124-B29]) populations. Further functional studies are required to confirm that the pathogenic missense variants found in this study are indeed gain-of-function variants ([@djz124-B35]).

In conclusion, variants predicted to alter function of *BRCA2*, *HOXB13*, and *ATM* were associated with PCa, and patients with a pathogenic variant showed specific demographic and clinical characteristics. The findings reported in this study may inform future genetic testing for PCa.
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